Pak, Ekaterina <br/><br/>
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.  [electronic resource] 

 -  Neuro-oncology  09 2019 
 - 1150-1163 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1523-5866 
<br/><br/><label>Standard No.: </label>10.1093/neuonc/noz089  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anilides<br/>Animals<br/>Biphenyl Compounds<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Cerebellar Neoplasms--drug therapy<br/>Drug Resistance, Neoplasm--genetics<br/>Hedgehog Proteins--drug effects<br/>High-Throughput Screening Assays<br/>Histone Deacetylase Inhibitors--pharmacology<br/>Hydroxamic Acids--pharmacology<br/>Inhibitory Concentration 50<br/>Medulloblastoma--drug therapy<br/>Mice<br/>Proteins--genetics<br/>Pyridines<br/>Repressor Proteins--genetics<br/>Signal Transduction<br/>Smoothened Receptor--antagonists & inhibitors